tranilast and Otitis-Media-with-Effusion

tranilast has been researched along with Otitis-Media-with-Effusion* in 2 studies

Trials

2 trial(s) available for tranilast and Otitis-Media-with-Effusion

Article	Year
Clinical efficacy of Tranilast on otitis media with effusion in children. Auris, nasus, larynx, 1994, Volume: 21, Issue:3 In this open randomized study, we evaluated the efficacy of Tranilast, one of the anti-inflammatory drugs, on otitis media with effusion in children. Sixty-two patients (103 ears) were divided into two groups: Group A was given Tranilast and local treatment (nasal and tubal); Group B only received local treatment (control for Group A). The overall improvement rating assessed as "moderately improved or above" for Group A was 63.6%, Group B 47.9%. There was a significant improvement in Group A as compared to Group B (p < 0.05). In subjects who suffered from otitis media with effusion for over 2 months. Group A exhibited 50.0% of efficacy while Group B only 15.4% (p < 0.05). Topics: Acoustic Impedance Tests; Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Audiometry; Child; Child, Preschool; Ear, Middle; Female; Humans; Infant; Infant, Newborn; Male; ortho-Aminobenzoates; Otitis Media with Effusion; Treatment Outcome; Tympanic Membrane	1994
Use of Tranilast [N-(3,4-dimethoxycinnamoyl) anthranilic acid] in secretory otitis media. Annals of allergy, 1992, Volume: 68, Issue:5 Treatment with Tranilast of 45 patients (87 ears) with secretory otitis media was studied. Tranilast was administered orally for at least 1 month. The evaluation of its effectiveness was based on changes in subjective symptoms, tympanic membrane findings, hearing level, and tympanometry. Subjects were divided into three groups: allergy group (group I), nonallergy group (group II) and deformity-disorder group (group III). The respective percentages of Tranilast efficacy for these three groups were 46.2%, 42.1%, and 10.0%, respectively. Equivalent effectiveness was demonstrated whether or not allergies were present. After Tranilast administration, the drug and its metabolites were found in MEE samples from all the patients. Anaphylatoxin (C3a, C5a) activities in the MEE were shown to decrease gradually after Tranilast administration. Tranilast may be effective for treating secretory otitis media because it directly suppresses anaphylatoxin present in middle ear effusion. Topics: Administration, Oral; Adult; Child; Child, Preschool; Complement C3a; Complement C5a; Ear, Middle; Exudates and Transudates; Histamine H1 Antagonists; Humans; Middle Aged; ortho-Aminobenzoates; Otitis Media with Effusion	1992

Article

Year

Clinical efficacy of Tranilast on otitis media with effusion in children.

Auris, nasus, larynx, 1994, Volume: 21, Issue:3

In this open randomized study, we evaluated the efficacy of Tranilast, one of the anti-inflammatory drugs, on otitis media with effusion in children. Sixty-two patients (103 ears) were divided into two groups: Group A was given Tranilast and local treatment (nasal and tubal); Group B only received local treatment (control for Group A). The overall improvement rating assessed as "moderately improved or above" for Group A was 63.6%, Group B 47.9%. There was a significant improvement in Group A as compared to Group B (p < 0.05). In subjects who suffered from otitis media with effusion for over 2 months. Group A exhibited 50.0% of efficacy while Group B only 15.4% (p < 0.05).

Topics: Acoustic Impedance Tests; Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Audiometry; Child; Child, Preschool; Ear, Middle; Female; Humans; Infant; Infant, Newborn; Male; ortho-Aminobenzoates; Otitis Media with Effusion; Treatment Outcome; Tympanic Membrane

1994

Use of Tranilast [N-(3,4-dimethoxycinnamoyl) anthranilic acid] in secretory otitis media.

Annals of allergy, 1992, Volume: 68, Issue:5

Treatment with Tranilast of 45 patients (87 ears) with secretory otitis media was studied. Tranilast was administered orally for at least 1 month. The evaluation of its effectiveness was based on changes in subjective symptoms, tympanic membrane findings, hearing level, and tympanometry. Subjects were divided into three groups: allergy group (group I), nonallergy group (group II) and deformity-disorder group (group III). The respective percentages of Tranilast efficacy for these three groups were 46.2%, 42.1%, and 10.0%, respectively. Equivalent effectiveness was demonstrated whether or not allergies were present. After Tranilast administration, the drug and its metabolites were found in MEE samples from all the patients. Anaphylatoxin (C3a, C5a) activities in the MEE were shown to decrease gradually after Tranilast administration. Tranilast may be effective for treating secretory otitis media because it directly suppresses anaphylatoxin present in middle ear effusion.

Topics: Administration, Oral; Adult; Child; Child, Preschool; Complement C3a; Complement C5a; Ear, Middle; Exudates and Transudates; Histamine H1 Antagonists; Humans; Middle Aged; ortho-Aminobenzoates; Otitis Media with Effusion

1992